


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently Amended). 1. ~~A Compound~~ compound of formula A,

A:



or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of naphthylmethyl, naphthylethyl, anthracenylmethyl, anthracenylethyl, ~~pyrenylmethyl~~, R^1 , R^2 , R^3 , R^4 are selected from at least one of hydrogen, alkyl, cycloalkyl, alkylaryl, ~~para-toluenesulfonyl~~, ~~arenesulfonyl~~, ~~alkylsulfonyl~~, ~~acyl~~, ~~carbamoyl~~, where X is at least one of cycloalkyl and $(\text{CH}_2)_r$, and r is 2-18, where Y is at least one of cycloalkyl and $(\text{CH}_2)_s$ and s is 2-18.

Claim 2 (Currently Amended). The compound according to claim 1, wherein R is selected from the group consisting of naphthylmethyl, naphthylethyl, anthracenylmethyl, anthracenylethyl, ~~pyrenylmethyl~~, R^1 , R^2 , R^3 , and R^4 are hydrogen and r and s are 2 – 5 or a pharmaceutically acceptable salt thereof.

3 (Original): The compound according to claim 1, which is *N*-(3-Amino-propyl)-*N*-anthracen-9-ylmethyl-butane-1, 4-diamine, trihydrochloride or a pharmaceutically acceptable salt thereof.

4 (Original): The compound according to claim 1, which is *N*-(4-Amino-butyl)-*N*-anthracen-9-ylmethyl-butane-1, 4-diamine, trihydrochloride or a pharmaceutically acceptable salt thereof.

5 (Original): The compound according to claim 1, which is *N*-(4-Amino-butyl)-*N*-anthracen-9-ylmethyl-pentane-1, 5-diamine, trihydrochloride or a pharmaceutically acceptable salt thereof.

6 (Original): The compound according to claim 1, which is, *N*-(4-Amino-butyl)-*N'*-naphthalen-1-ylmethyl-butane-1, 4-diamine, trihydrochloride or a pharmaceutically acceptable salt thereof.

7 (Cancelled)

8 (Original): The compound according to claim 1, which is *N*-{4-[(Anthracen-9-ylmethyl)-amino]-butyl}-cyclohexane-1, 4-diamine, trihydrochloride or a pharmaceutically acceptable salt thereof.

9 (Currently Amended): A compound of the formula B,

B: $\text{RNR}^1(\text{CH}_2)_r\text{NR}^2(\text{CH}_2)_s\text{NR}^3(\text{CH}_2)_t\text{NR}^4\text{R}^5$

or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of naphthylmethyl, naphthylethyl, anthracenylmethyl, anthracenylethyl, pyrenylmethyl, wherein R¹, R², R³, R⁴, and R⁵ are selected from at least one of the following: hydrogen, alkyl, cycloalkyl, alkylaryl, ~~para-toluenesulfonyl, arenesulfonyl, alkylsulfonyl, acyl, carbamoyl~~ and r is 2-18, s is 2-18 and t is 2-18.

10 (Original): The compound according to claim 9, wherein R¹, R², R³, R⁴, and R⁵ are hydrogen or a pharmaceutically acceptable salt thereof.

11 (Original): The compound according to claim 10, wherein r, s and t are 2-5.

12 (Original): The compound according to claim 9, which is *N*-[4-(4-Amino-butylamino)-butyl]-*N*-anthracen-9-ylmethyl-butane-1, 4-diamine, tetrahydrochloride or a pharmaceutically acceptable salt thereof.

13 (Original): The compound according to claim 9, which is *N*-[4-(4-Amino-butylamino)-butyl]-*N*-anthracen-9-ylmethyl-pentane-1, 5-diamine, tetrahydrochloride or a pharmaceutically acceptable salt thereof.

14 (Cancelled)

15 (Cancelled)

16 (Cancelled)

17 (Cancelled)

18 (Cancelled)

19 (Cancelled)

20 (Original): The pharmaceutical composition comprising an anti-neoplastic effective amount of a polyamine according to claim 1 and a pharmaceutically acceptable carrier thereof.

21 (Original): The pharmaceutical composition comprising an anti-neoplastic effective amount of a polyamine according to claim 9 and a pharmaceutically acceptable carrier thereof.

22 (Cancelled)

23 (Cancelled)

24 (Cancelled)

25 (Cancelled)

26 (Cancelled)

27 (Cancelled)

28 (Cancelled)


29 (Cancelled)

30 (Cancelled)

31 (New) The compound according to claim 1 that is useful in vectoring systems that attach to anti-cancer drugs to improve chemotherapeutic potency without involving the immune system.

32 (New) A compound of formula A,

A:



or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of naphthylmethyl, naphthylethyl, anthracenylmethyl, anthracenylethyl, pyrenylmethyl, R¹, R², R³, R⁴ are selected from at least one of hydrogen, alkyl, cycloalkyl, alkylaryl, where X is at least one of cycloalkyl and (CH₂)_r, and r is 2-18, where Y is at least one of cycloalkyl and (CH₂)_s and s is 2-18 that is useful in vectoring systems that attach to anti-cancer drugs to improve chemotherapeutic potency.

33 (New) The compound according to claim 32, which is *N*-(4-Amino-butyl)-*N*'-pyren-1-ylmethyl-butane-1,4-diamine, trihydrochloride or a pharmaceutically acceptable salt thereof.